HBM9014 / Harbour BioMed - LARVOL DELTA

HBM9014, a first-in-class fully human anti-LIFR antibody with excellent preclinical efficacy and safety profile (AACR 2024) - "HBM9014 specifically binds to the key component of LIF and CLCF1 receptor, LIFR, thus blocks both LIF and CLCF1 signaling pathways. HBM9014 shows significant cell proliferation inhibition alone or in combo with small molecule inhibitors in 3D culture of multiple cancer cell lines. It also shows significant in vivo antitumor efficacy as monotherapy, and enhanced efficacy in combination with Cisplatin in multiple mouse models."

Preclinical • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Head and Neck Cancer • Hematological Malignancies • Leukemia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • IL6 • LIF • LIFR

HBM9014 Is a Fully Human Anti-LIFR Antibody with Excellent Preclinical Efficacy and Safety Profile (PEGS 2023) - No abstract available

Preclinical • LIFR

Harbour BioMed Reports Full Year 2022 Financial Results (PRNewswire) - "In addition, HBM7022 (CLDN18.2xCD3), HBM7004 (B7H4x4-1BB), HBM9027 (PD-L1xCD40), HBM9033 (MSLN ADC), HBM1047 (CD200R1) and HBM9014 (LIFR) are all preclinical stage products in the company's pipeline. With the efficient output of the technology platforms as well as the rich expertise of our R&D team, the Company aims to file at least one IND each year moving forward."

IND • Oncology • Solid Tumor